Meridian Bioscience Inc. (VIVO) Social Stream
MERIDIAN BIOSCIENCE INC (VIVO) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering VIVO.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
The Trend in the Analyst Price Target
VIVO's average price target has moved up $7.33 over the prior 23 months.
VIVO reports an average of 11.88% for its upside potential over the past 44 weeks.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Share Price||Upside Potential|
VIVO Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
The Trend in the Broker Recommendations
Over the past 13 months, VIVO's average broker recommendation rating worsened by 2.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- MERIDIAN BIOSCIENCE INC's variance in analysts' estimates is lower than just about 100% of all US stocks.
- In the context of all US stocks, MERIDIAN BIOSCIENCE INC's number of analysts covering the stock is greater than 13.8% of them.
- MERIDIAN BIOSCIENCE INC's upside potential (average analyst target price relative to current price) is higher than 27.05% of stocks in the small market cap category.
- MERIDIAN BIOSCIENCE INC's average analyst price target is greater than 435.89% of stocks in the small market cap category.
In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to MERIDIAN BIOSCIENCE INC are LHDX, TKNO, and KROS.
What is the outlook for VIVO? Use POWR Ratings for clearer insight into price direction.